Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Chief Financial Officer | March 25, 2022 | March 28, 2022 |
| GRAIL, Inc.GRAL · Entity 4122 | Director | June 11, 2024 | June 12, 2024 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP, Chief Financial Officer | March 05, 2026 | March 09, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Chief Financial Officer | March 26, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date March 25, 2022 · Filed March 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,146 |
Reported balance
After 2022-03-25 transaction · row 1
1 source rowRow 1 · 2022-03-25 · Tax withholding · Disposed 1,254 · Balance 33,146 F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy Dhingra Family Revocable Trust | 5,000 |
Reported balance
Holding disclosure · report date 2022-03-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
GRAIL, Inc.
Report date June 11, 2024 · Filed June 12, 2024
This filing explicitly reported no securities owned.
ILLUMINA, INC.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,264 |
Reported balance
After 2026-03-05 transaction · row 1
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 9,358 · Balance 34,264 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, subject to awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2028-12-31 | Direct | 10,918 |
Reported balance
After 2026-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-05 · Grant · Acquired 10,918 · Balance 10,918 F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028 with vesting on December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2028-12-31 | Direct | 10,918 |
Reported balance
After 2026-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-05 · Grant · Acquired 10,918 · Balance 10,918 F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 31, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, subject to awardee's continuing status as a service provider on such dates.
F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028 with vesting on December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.
F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 31, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
Summit Therapeutics Inc.
Report date March 26, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Dhingra Family Revocable Trust | 354,958 |
Reported balance
After 2024-03-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-03-26 · Purchase · Acquired 100,000 · Balance 354,958 F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 9, 2026 21:04 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 10,918 | $128.24 | $1,400,124.32 |
DisclosureSEC source: 0001110803-26-000072 · form4.xml · derivative · entry 3 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,918 Underlying: Common Stock · 10,918 shares Expires 2028-12-31 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 31, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 31, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:04 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 10,918 | $128.24 | $1,400,124.32 |
DisclosureSEC source: 0001110803-26-000072 · form4.xml · derivative · entry 2 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,918 Underlying: Common Stock · 10,918 shares Expires 2028-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028 with vesting on December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028 with vesting on December 31, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:04 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 9,358 | $128.24 | $1,200,069.92 |
DisclosureSEC source: 0001110803-26-000072 · form4.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,264 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:20 UTC | ILLUMINA, INC. ILMN · Entity 3137 | PurchaseCommon Stock | 6,100 | $81.21 | $495,381.00 |
DisclosureSEC source: 0001127602-25-014280 · form4.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,906 F1 · price: Weighted average purchase price representing 6,100 shares purchased ranging from $81.16 to $81.21 per share. Number of shares purchased at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 11,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008707 · form4.xml · derivative · entry 3 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,437 Underlying: Common Stock · 11,437 shares Expires 2028-01-02 F4 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 2, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 2, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F4 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 2, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 2, 2028, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 11,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008707 · form4.xml · derivative · entry 2 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,437 Underlying: Common Stock · 11,437 shares Expires 2028-01-02 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2025-2027 with vesting on January 2, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2025-2027, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2025-2027 with vesting on January 2, 2028. The number of shares issued will range from 0% to 250% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2025-2027, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 9,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008707 · form4.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,806 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2026, February 15, 2027, February 15, 2028, and February 15, 2029, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Mr. Dhingra's unvested RSUs were increased by 177 units as a result of such adjustment. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 10,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014675 · form4.xml · derivative · entry 3 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,296 Underlying: Common Stock · 10,296 shares Expires 2027-01-03 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 10,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014675 · form4.xml · derivative · entry 2 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,296 Underlying: Common Stock · 10,296 shares Expires 2027-01-03 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 8,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014675 · form4.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,826 F1 · shares: Grant of restricted stock units with 25% of the shares subject to the award vesting on each of the first, second, third and fourth anniversaries of the date of grant, subject to the awardee's continuing to be a service provider on such dates. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:27 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 100,000 | $3.75 | $375,000.00 |
DisclosureSEC source: 0001599298-24-000046 · wk-form4_1711585608.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 354,958 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:49 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 19,700 | $2.17 | $42,749.00 |
DisclosureSEC source: 0001599298-23-000101 · wk-form4_1702504149.xml · nonDerivative · entry 2 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 254,958 F1 · shares: The Reporting Person purchased these shares in a single transaction on the open market. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:49 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 700 | $2.15 | $1,505.00 |
DisclosureSEC source: 0001599298-23-000101 · wk-form4_1702504149.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 235,258 F1 · shares: The Reporting Person purchased these shares in a single transaction on the open market. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 22:24 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 196,362 | $1.05 | $206,180.10 |
DisclosureSEC source: 0001849682-23-000004 · wf-form4_167831424008442.xml · nonDerivative · entry 2 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 234,558 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:49 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 24,658 | $0.97 | $23,918.26 |
DisclosureSEC source: 0001599298-22-000102 · wf-form4_166076931714249.xml · nonDerivative · entry 2 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 38,196 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:49 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 11,557 | $0.97 | $11,210.29 |
DisclosureSEC source: 0001599298-22-000102 · wf-form4_166076931714249.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,057 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| August 16, 2022 Filed Mar 8, 2023 21:58 UTC Amendment | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 24,658 | $0.97 | $23,918.26 |
DisclosureSEC source: 0001849682-23-000002 · wf-form4a_167831269908577.xml · nonDerivative · entry 2 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 38,196 F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2022 Filed Mar 8, 2023 21:58 UTC Amendment | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 13,027 | $0.97 | $12,636.19 |
DisclosureSEC source: 0001849682-23-000002 · wf-form4a_167831269908577.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,527 F1 · shares: This Form 4 is being amended to correct the number of shares purchased by the Reporting Person in the Issuer's rights offering. 1,470 shares were inadvertently omitted from the original filing. F1 · balance_after: This Form 4 is being amended to correct the number of shares purchased by the Reporting Person in the Issuer's rights offering. 1,470 shares were inadvertently omitted from the original filing. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:29 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 600,000 | Not disclosed Strike: $1.33 | Not disclosed |
DisclosureSEC source: 0001849682-22-000003 · wf-form4_165420535405545.xml · derivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2032-05-31 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on May 31, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on May 31, 2023 (the one-year anniversary of the grant date). Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 23:31 UTC | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 1,254 | $37.90 | $47,526.60 |
DisclosureSEC source: 0001217234-22-000070 · wf-form4_164851028685319.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,146 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:48 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 34,900 | $0.00 Strike: $41.32 | $0.00 |
DisclosureSEC source: 0001217234-22-000039 · wf-form4_164401490341588.xml · derivative · entry 3 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock · 34,900 shares Expires 2023-02-02 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 2, 2023 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:48 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 19,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000039 · wf-form4_164401490341588.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,400 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on February 2, 2023 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:19 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 5,000 | $42.34 | $211,693.50 |
DisclosureSEC source: 0001849682-21-000002 · wf-form4_163822074936329.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Dhingra Family Revocable Trust Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.91 to $42.72, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $63.43 | $0.00 |
DisclosureSEC source: 0001217234-21-000059 · wf-form4_161670936613832.xml · derivative · entry 2 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-03-25 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest on March 25, 2022 and 1/48th of the shares subject to the option shall vest at the end of each calendar month thereafter. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 21:56 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 14,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000059 · wf-form4_161670936613832.xml · nonDerivative · entry 1 Dhingra Ankur · CIK 0001849682 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on March 25, 2022 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.